Sponsor or institution

Clinical trials and research at Suzhou Zelgen Biopharmaceuticals Co.,Ltd

• 14Clinical trials
• 2Countries

Newest trials

All recruiting trials (14)

• ZGGS34 treatment for adults with advanced solid tumors

  This trial will try the experimental drug ZGGS34 in adults with advanced MUC17-positive solid tumors to see if it is safe and can shrink tumors.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Zhengzhou, Henan · NCT07258121

• ZG006 plus PD‑1/PD‑L1 immunotherapy as first‑line treatment for extensive‑stage small cell lung cancer

  This study will test whether adding ZG006 to PD‑1/PD‑L1 immunotherapy (with or without chemotherapy) is safe and improves outcomes for people with extensive‑stage small cell lung cancer starting first‑line treatment.

  Recruiting Phase 1 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Shanghai, Shanghai Municipality · NCT07231445

• ZG006 versus investigator-selected chemotherapy for relapsed small-cell lung cancer

  This trial tests whether ZG006 helps people with relapsed small-cell lung cancer live longer than the chemotherapy their doctor would choose.

  Recruiting Phase 3 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Shanghai, Shanghai Municipality · NCT07189455

• ZG005 with gemcitabine and cisplatin for advanced gallbladder cancer

  This test tries whether adding ZG005 to gemcitabine and cisplatin helps people with advanced gallbladder cancer as their first treatment.

  Recruiting Phase 2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Hefei, Anhui · NCT07099547

• ZG005 plus gecacitinib (with or without bevacizumab) for advanced cervical cancer

  This trial will test whether adding the experimental antibody ZG005 to the JAK inhibitor gecacitinib, with or without bevacizumab, is safe and shows signs of benefit in adults with advanced cervical cancer.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Hangzhou, Zhejiang · NCT07080216

• ZG006 plus ZG005 for advanced small cell lung cancer and neuroendocrine carcinoma

  This trial tests whether the combination of ZG006 and ZG005 helps adults with advanced small cell lung cancer or neuroendocrine carcinoma.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Guanzhou, Guangdong · NCT07038096

• ZGGS18 and ZG005 combination for advanced solid tumors

  This tests whether giving ZGGS18 together with ZG005 is safe and might help adults (18–75) with advanced solid tumors who have not responded to standard treatments.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Guangzhou, Guangdong · NCT06938880

• ZG005 plus gecacitinib for advanced non-small cell lung cancer

  This trial tests whether giving ZG005 by injection together with oral gecacitinib is safe and may help adults 18–75 with advanced non-small cell lung cancer that progressed after PD‑1/PD‑L1 therapy.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Shanghai, Shanghai Municipality · NCT06903377

• ZG005 with gecacitinib for relapsed or refractory lymphoma

  We are testing whether ZG005 given with gecacitinib is safe and helps adults whose lymphoma has come back or hasn't responded to prior treatments.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Hangzhou, Zhejiang · NCT06883526

• Testing ZG006 for small cell lung cancer patients who have not responded to standard treatments

  This study is testing a new treatment called ZG006 for people with small cell lung cancer who haven't had success with standard treatments to see if it can help them.

  Recruiting at 3 sites Phase 1 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Orange, California and 5 other locations · NCT06592638

• Testing ZG006 for advanced small cell lung cancer and neuroendocrine carcinoma

  This study is testing a new drug called ZG006 to see if it is safe and effective for people with advanced small cell lung cancer or neuroendocrine carcinoma.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Beijing, Beijing Municipality · NCT06440057

• Testing ZG006 for advanced small cell lung cancer and neuroendocrine carcinoma

  This study is testing a new treatment called ZG006 to see if it is safe and effective for people with advanced small cell lung cancer and neuroendocrine carcinoma.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Shanghai, Shanghai Municipality · NCT06283719

• Treatment of small cell lung cancer and neuroendocrine carcinoma with ZG006

  This study is testing a new drug called ZG006 to see if it can help adults with small cell lung cancer or neuroendocrine carcinoma who have run out of other treatment options.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Zhengzhou, Henan · NCT05978284

• Testing ZGGS18 in patients with advanced solid tumors

  This study is testing a new drug called ZGGS18 in people with advanced solid tumors to see if it's safe and how well it works when other treatments haven't helped.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Beijing, Beijing Municipality · NCT05584800

Quick answers

How many clinical trials run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (13 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 10, Phase 1: 2, Phase 3: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →